Plant Breeding and CRISPR Plants Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Demand for Climate-Resilient Crop Traits

Climate stress converts trait performance into a measurable field variable, enabling breeding programs to be funded based on yield retained under drought, salinity, and heat rather than on potential yield alone. According to the Indian Council of Agricultural Research (ICAR), its genome-edited variety Pusa DST Rice 1 can increase yields by 9.66% to 30.4% in saline and alkaline soils as of 2025^[1]. Quantified stress-condition gains in an established cultivar background give breeders a defensible return case, directing funding toward trait discovery, editing platforms, and licensing across public and commercial breeding programs.

Food-Security Pressure and Yield-Stability Requirements

Yield stability is a distinct breeding objective from yield potential, as buyers of genetics pay for output that holds when weather conditions turn unfavorable. According to the Food and Agriculture Organization of the United Nations (FAO), global wheat production in 2026/27 is projected to decline by 3.8% to 810.9 million metric tons due to smaller harvests in major exporting countries^[2]. Supply concentrated in weather-exposed exporters turns seasonal variance into a food-security risk, sustaining funding for traits and breeding tools that narrow the gap between good and poor years.

Regulatory Acceptance of Gene-Edited Crops

Regulatory classification determines the development cost and timeline for an edited variety, as GMO authorization requires risk assessment, dossier preparation, and several years before commercial release. According to the Official Journal of the European Union, Regulation (EU) 2026/1388 entered into force on 16 July 2026 and will apply from 17 July 2028, placing category 1 plants outside GMO rules subject to a verification procedure. A defined, shorter regulatory route allows breeders to plan programs against a known timeline, supporting pipeline commitments across crops and techniques.

Artificial Intelligence-Enabled Breeding and High-Throughput Phenotyping

Selection decisions depend on how quickly a program can link genotype data to measured field performance, as each cycle is limited by phenotyping capacity rather than sequencing cost. Unmanned aerial and sensor-based imaging can now capture canopy traits across entire trials in a single pass, and machine learning models convert those readings into predictions that rank lines before harvest. Shorter, better-informed cycles improve the return on every trait a program develops, which sustains spending on phenotyping platforms, analytics, and the breeding tools that act on the results.

High Research and Development, Field-Trial, and Commercialization Costs

Advancing an edited variety from target discovery through multisite field trials to regulatory submission requires sustained annual spending, not a one-time project budget. BASF SE reported that its Agricultural Solutions segment recorded research and development expenses of EUR 990 million (USD 1.09 billion) in 2025^[3]. This level of expenditure sets the practical threshold for running a full commercial program. Organizations unable to fund containment facilities, genotyping capacity, and location-specific trials across jurisdictions advance fewer candidates to launch, limiting the number of products reaching growers.

Intellectual-Property Concentration and Access Constraints

Freedom-to-operate must be cleared before an edited line can be commercialized, as the nuclease, guide sequence, delivery method, and resulting trait can each carry separate rights. According to the Swiss Federal Institute of Intellectual Property (IPI), its 2025 CRISPR patent and license landscape for plants counted 23,696 patent families on CRISPR, based on data up to and including December 2024. Clearing an estate of that size requires legal search and negotiation before any fieldwork begins, and unresolved rights stall candidates, limiting the number of programs that reach commercialization.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Plant Breeding and CRISPR Plants Market Segment Analysis

Biotechnological breeding accounted for the largest 62.0% of the plant breeding and the CRISPR plants market share in 2025. This position reflects sustained investment in genomics, genetic selection, and editing capabilities within commercial and public pipelines. Genome editing and CRISPR represent the fastest-growing area within this segment. Conventional breeding remains central for complex polyploid crops, including wheat, where trait architecture resists simple intervention, while biotechnology tools are becoming accessible to a wider range of programs. Mutation breeding retains a defined role, as induced variation continues to deliver useful diversity for selection in specific crops.

Biotechnological breeding is projected to grow at the fastest CAGR of 11.8% from 2026 to 2031. Marker-assisted selection, genomic selection, and genome editing are increasingly deployed together rather than as separate approaches. Genomic selection and artificial intelligence models narrow germplasm pools before precise edits are introduced, reducing costly field-evaluation cycles and shortening the time to advancement decisions. Integrated platforms address multiple crops and traits from a single capability base, sustaining demand for reagents, informatics, transformation services, and trained personnel across public and commercial programs.

CRISPR-Cas9 accounted for the largest share at 36.0% in 2025. Established delivery systems, broad crop applicability, and extensive published validation keep it a foundational tool in commercial and public programs. High-throughput phenotyping and AI-assisted breeding serve as significant non-editing platforms, making trial evaluation more effective at a commercial scale. Sequencing, genotyping, and bioinformatics benefit from lower costs and wider deployment. Transcription activator-like effector nucleases (TALENs), MegaTALs, and zinc finger nucleases (ZFNs) retain relevance where CRISPR delivery is less effective and where legacy investment continues to support their use in defined programs.

Base editing is projected to grow at the fastest CAGR of 17.0% from 2026 to 2031. The category sits alongside CRISPR-Cas9, including CRISPR-Cas12a and prime editing, and these newer tools enable highly specific changes without requiring double-strand DNA breaks. This property suits traits governed by known point variants in coding or promoter regions and reduces the screening burden associated with unintended outcomes. Licensing arrangements for newer editors are drawing commercial programs into evaluation agreements as these editors extend precision-editing work across crops and target species.

Herbicide tolerance accounted for the largest share at 30.5% in 2025. This position reflects established weed-management practices in row-crop agriculture, where growers apply these traits within existing crop protection and seed-purchasing systems. Familiar agronomic handling and predictable field outcomes support continued specification by seed companies. Regulatory treatment varies by jurisdiction, and herbicide-tolerant plants developed through new genomic techniques face more stringent authorization requirements in some markets than other edited plants. Disease resistance, drought resistance, and salinity tolerance remain substantial areas of ongoing crop development activity across major field and horticultural crops.

The plant breeding and the CRISPR plants market size for nutritional enhancement and biofortification is projected to grow at the fastest CAGR of 16.9% from 2026 to 2031. These traits support food-manufacturing partnerships that monetize benefits beyond the farm gate, as composition can be specified contractually by processors. Multi-disease resistance work in corn and other staples continues alongside this. Shelf-life and quality improvement, carbon sequestration, and nitrogen-use efficiency also create differentiated positions, giving developers routes to recover trait costs through channels other than seed price alone in commercial markets.

Cereals and grains accounted for the largest share at 39.0% in 2025. Corn, wheat, rice, sorghum, and barley are the subject of extensive breeding activity, cover major cultivated areas, and supply a large share of dietary calories worldwide. Established seed distribution channels and long-standing public breeding infrastructure support the trial capacity required for variety advancement. Hybrid wheat programs are advancing through germplasm agreements aimed at commercialization in Europe and North America. Reference genomes and dense marker resources for these species reduce the technical work required before editing programs begin in a new crop.

Fruits and vegetables are projected to grow at the fastest CAGR of 15.5% from 2026 to 2031. Specialty crops command premium prices for seedlessness, flavor, shelf life, and disease resistance, making trait development commercially attractive even at lower volumes. Many of these species are vegetatively propagated or highly heterozygous, making trait introduction through repeated crossing slow and disruptive to an established variety. Oilseeds and pulses remain important for soybean and canola trait stacks, while turf and ornamental, forage and cover, and industrial and bioenergy crops retain smaller roles in the segment.

Commercial agriculture accounted for the largest share at 52.0% in 2025. Seed and trait deployment in staple grains supports this position across the Americas and Asia-Pacific, where seed companies convert traits into varieties, manage multisite trials, and handle registration in each country of sale. Their volumes justify dedicated editing groups, transformation facilities, and regulatory affairs teams. Horticulture remains relevant because precision editing can deliver fruit and vegetable traits that would otherwise require long breeding cycles. Commercial buyers set specification requirements that shape how upstream tool providers package their offerings.

Research and public breeding programs are projected to grow at the fastest CAGR of 13.8% from 2026 to 2031. International research institutes have secured long-term humanitarian licenses for gene editing in smallholder crops across Asia and Africa, making editing capabilities available to programs without commercial licensing budgets. Food production and animal feed applications benefit from higher protein content and improved amino acid profiles. Pharmaceutical and specialty crops can benefit from precise changes in secondary metabolite pathways, while biofuel and biochemical production remains at an early stage within the plant breeding and CRISPR plant industry.

Geography Analysis

North America accounted for the largest share at 35.1% in 2025. The United States operates an Animal and Plant Health Inspection Service pathway that allows certain gene-edited crops without introduced foreign sequences to proceed outside the review process applied to transgenic events, providing developers with early clarity on their regulatory route. Canada uses a novelty-based assessment approach that evaluates the trait rather than the breeding method. Mexico remains relevant for commercial seed production and off-season nurseries. Large planted areas in corn, soybean, and cotton support extensive trial capacity across the region.

Asia-Pacific is projected to grow at the fastest CAGR of 14.0% from 2026 to 2031. China has approved gene-edited crop events covering soybean, corn, wheat, and rice, and India has released and begun seed multiplication of genome-edited rice ahead of commercial deployment. Japan has commercial experience with genome-edited produce, including a gamma-aminobutyric acid-enriched tomato, while South Korea and Australia are expanding their pipelines. Regional germplasm holdings and local partnerships carry considerable weight, and companies with domestic breeding relationships and distribution reach are better positioned to convert approvals into planted area.

Europe is preparing for the implementation of the new genomic techniques framework, with breeders moving editing work from research into product development and field trials. Public financing is supporting that shift. According to the European Investment Bank (EIB), in 2026, it will lend Limagrain EUR 300 million (USD 324 million) to accelerate the development of more productive and resilient crops through a research program led by Vilmorin and Cie. The Middle East is investing in desert-adapted crop genetics, while Africa is advancing through public programs and international research partnerships focused on staple crops.